Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Authors:
- Eric L. SimpsonESEric L. Simpson
- Thomas BieberTBThomas Bieber
- Emma Guttman-YasskyEGEmma Guttman-Yassky
- Lisa A. BeckLBLisa A. Beck
- Andrew BlauveltABAndrew Blauvelt
- Michael J. CorkMCMichael J. Cork
- Jonathan I. SilverbergJSJonathan I. Silverberg
- Mette DeleuranMDMette Deleuran
- Yoko KataokaYKYoko Kataoka
- Jean-Philippe LacourJLJean-Philippe Lacour
- Külli KingoKKKülli Kingo
- Margitta WormMWMargitta Worm
Top Cited Papers
- 15 December 2016
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 375 (24) , 2335-2348
Abstract
Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. In two randomized, placebo-controlled, phase 3 trials of identical design (SOLO 1 and SOLO 2), we enrolled adults with moderate-to-severe atopic dermatitis whose disease was inadequately controlled by topical treatment. Patients were randomly assigned in a 1:1:1 ratio to receive, for 16 weeks, subcutaneous dupilumab (300 mg) or placebo weekly or the same dose of dupilumab every other week alternating with placebo. The primary outcome was the proportion of patients who had both a score of 0 or 1 (clear or almost clear) on the Investigator’s Global Assessment and a reduction of 2 points or more in that score from baseline at week 16. We enrolled 671 patients in SOLO 1 and 708 in SOLO 2. In SOLO 1, the primary outcome occurred in 85 patients (38%) who received dupilumab every other week and in 83 (37%) who received dupilumab weekly, as compared with 23 (10%) who received placebo (P<0.001 for both comparisons with placebo). The results were similar in SOLO 2, with the primary outcome occurring in 84 patients (36%) who received dupilumab every other week and in 87 (36%) who received dupilumab weekly, as compared with 20 (8%) who received placebo (P<0.001 for both comparisons). In addition, in the two trials, an improvement from baseline to week 16 of at least 75% on the Eczema Area and Severity Index was reported in significantly more patients who received each regimen of dupilumab than in patients who received placebo (P<0.001 for all comparisons). Dupilumab was also associated with improvement in other clinical end points, including reduction in pruritus and symptoms of anxiety or depression and improvement in quality of life. Injection-site reactions and conjunctivitis were more frequent in the dupilumab groups than in the placebo groups. In two phase 3 trials of identical design involving patients with atopic dermatitis, dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo. Trials of longer duration are needed to assess the long-term effectiveness and safety of dupilumab. (Funded by Sanofi and Regeneron Pharmaceuticals; SOLO 1 ClinicalTrials.gov number, NCT02277743; SOLO 2 ClinicalTrials.gov number, NCT02277769.)Keywords
This publication has 37 references indexed in Scilit:
- ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patientsJournal of the European Academy of Dermatology and Venereology, 2016
- Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adultsJournal of the American Academy of Dermatology, 2016
- The Role of the Skin Microbiome in Atopic DermatitisCurrent Allergy and Asthma Reports, 2015
- Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitisJournal of Allergy and Clinical Immunology, 2014
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic DermatitisNew England Journal of Medicine, 2014
- Impacto de la calidad de vida relacionada con la salud en población pediátrica y adulta española con dermatitis atópica. Estudio PSEDAActas Dermo-Sifiliograficas, 2013
- Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitisJournal of Allergy and Clinical Immunology, 2012
- Guidelines for treatment of atopic eczema (atopic dermatitis) Part IJournal of the European Academy of Dermatology and Venereology, 2012
- Atopic dermatitis: a disease of altered skin barrier and immune dysregulationImmunological Reviews, 2011